MBBC vs NBIX · P/E 33, rev $8.8M vs P/E 45, rev $1.77B
Marathon Bancorp, Inc. Common Stock (MBBC) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Marathon Bancorp, Inc. Common Stock (MBBC) is a banks - regional company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MBBC revenue for 2026-03-31 was $8.8M. Net income was $1.4M. Revenue was up 51.0% from 2025-12-31 to 2026-03-31. MBBC currently screens at market cap $29.4M and trailing P/E 33.3.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MBBC currently screens at market cap $29.4M and trailing P/E 33.3. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MBBC and NBIX stock pages for the full models.
Not investment advice.